Showing 1641-1650 of 3038 results for "".
- Novartis Acquires Gyroscope Therapeutics, Maker of Investigational Gene Therapy for Geographic Atrophyhttps://modernod.com/news/novartis-acquires-gyroscope-therapeutics-maker-of-investigational-gene-therapy-for-geographic-atrophy/2480532/Novartis has bolstered it gene therapy portfolio after entering into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics. Novartis will make an upfront payment of $800 million and potential additi
- Optimo Medical Raises Additional CHF 1.8m to Expand Eye Surgery Planning Portfoliohttps://modernod.com/news/optimo-medical-raises-additional-chf-18m-to-expand-eye-surgery-planning-portfolio/2480363/Optimo Medical has successfully closed a 1.8 million Swiss Franc ($1.95 million) finance round, and now looks to expand its product portfolio in eye surgery planning. The funding will help establish recent partnerships with Ansys and MicroSurgical Technology to equip eye surgeons
- Norlase Receives CE Mark Approval for LION Green Laser Systemhttps://modernod.com/news/norlase-receives-ce-mark-approval-for-lion-green-laser-system/2478718/Norlase announced that it has been granted the European CE Mark for the LION green laser system. LION combines the Keeler Vantage Plus diagnostic indirect with Norlase’s compact laser technology into one device. With LION’s untethered and portable design, physicians can move freely between treatm
- EPA Approves Two Lysol Products as the First to Effectively Kill Novel Coronavirus on Surfaceshttps://modernod.com/news/epa-approves-two-lysol-products-as-the-first-to-effectively-kill-novel-coronavirus-on-surfaces/2477986/The US Environmental Protection Agency has approved two Lysol products as effective against the novel coronavirus when used on hard, non-porous surfaces, according to a CNN
- Quest Diagnostics Launches First Consumer-Ordered COVID-19 Antibody Testhttps://modernod.com/news/quest-diagnostics-launches-first-consumer-ordered-covid-19-antibody-test/2477674/For about $120, anyone can get now get a COVID-19 antibody test from Quest Diagnostics. The lab company announced Tuesday it launched the first consumer-ordered test—yes, that means there’s no doctor referral needed—to allow patients to check whether they have the antibodies that indicate t
- Astellas Announces Acquisition of Quethera, Maker of Gene Therapy Program for Glaucomahttps://modernod.com/news/astellas-announces-acquisition-of-quethera-maker-of-gene-therapy-program-for-glaucoma/2479949/Astellas Pharma has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma. Under the terms of the agreement, Astellas may pay up to £85 million ($1
- NTC to Strengthen Its Ophthalmology Portfolio Through the Acquisition of Ocular Antibiotic Productshttps://modernod.com/news/ntc-to-strengthen-its-ophthalmology-portfolio-through-the-acquisition-of-ocular-antibiotic-products/2480127/The Italian pharmaceutical company NTC announced the acquisition of some Novartis ocular antibiotic products, including broad spectrum antibiotic therapies to treat eye diseases. Countries covered under the agreement include Spain, Portug
- Orbis Flying Eye Hospital Begins 2-Week Training Project to Improve Eye Care Across Rwandahttps://modernod.com/news/orbis-flying-eye-hospital-begins-two-week-training-project-to-improve-eye-care-across-rwanda/2482898/The Orbis Flying Eye Hospital landed in Kigali, Rwanda, on July 18, 2025, marking the beginning of a historic 2-week training project. It marks the first time this aircraft has visited Rwanda, where Orbis' teams of clinical staff and volunteer faculty will work alongside t
- Opthea Treats Final Patient in Phase 3 COAST Trial for Wet AMDhttps://modernod.com/news/opthea-treats-final-patient-in-phase-3-coast-trial-for-wet-amd/2482668/Opthea announced that it has completed the final week 52 patient visit in COAST, the first of two phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with aflibercept (COAST) or ranibizumab (ShORe), compared to standard of care alone for the treatm
- Alcon to Showcase Latest Innovations at AAO 2024 Annual Meetinghttps://modernod.com/news/alcon-to-showcase-latest-innovations-at-aao-2024-annual-meeting/2482489/Alcon will unveil its latest clinical data and product innovations at the American Academy of Ophthalmology (AAO) 2024 annual meeting. Attendees, including ophthalmologists, surgical staff, researchers, and industry leaders, are invited to visit Alcon at booth #4008 for hands-on demonstrations an